SG Americas Securities LLC Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

SG Americas Securities LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 5,627 shares of the company's stock, valued at approximately $357,000.

A number of other institutional investors also recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in Verona Pharma PLC American Depositary Share by 14.0% during the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company's stock valued at $117,000 after buying an additional 225 shares during the period. Townsquare Capital LLC increased its stake in shares of Verona Pharma PLC American Depositary Share by 1.9% in the 4th quarter. Townsquare Capital LLC now owns 17,958 shares of the company's stock worth $834,000 after acquiring an additional 332 shares in the last quarter. NBC Securities Inc. purchased a new position in Verona Pharma PLC American Depositary Share during the 1st quarter valued at about $34,000. Geode Capital Management LLC lifted its position in Verona Pharma PLC American Depositary Share by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 62,741 shares of the company's stock valued at $2,914,000 after acquiring an additional 660 shares during the period. Finally, Vermillion Wealth Management Inc. bought a new stake in Verona Pharma PLC American Depositary Share during the fourth quarter worth about $46,000. 85.88% of the stock is owned by institutional investors.

Verona Pharma PLC American Depositary Share Price Performance

Shares of NASDAQ VRNA opened at $95.11 on Thursday. The firm has a market cap of $8.10 billion, a P/E ratio of -47.56 and a beta of 0.21. Verona Pharma PLC American Depositary Share has a twelve month low of $14.14 and a twelve month high of $99.01. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07. The company has a 50 day moving average of $76.98 and a 200 day moving average of $63.25.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.49. The business had revenue of $98.65 million during the quarter, compared to the consensus estimate of $41.47 million. As a group, research analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Mark W. Hahn sold 400,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total value of $4,560,000.00. Following the sale, the chief financial officer now owns 12,278,992 shares in the company, valued at approximately $139,980,508.80. This trade represents a 3.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kathleen A. Rickard sold 114,984 shares of Verona Pharma PLC American Depositary Share stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $8.82, for a total transaction of $1,014,158.88. Following the completion of the sale, the insider now directly owns 2,546,472 shares of the company's stock, valued at approximately $22,459,883.04. This trade represents a 4.32% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,965,800 shares of company stock worth $20,056,881. 4.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald raised their target price on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a research note on Wednesday, June 11th. Roth Capital restated a "buy" rating and issued a $116.00 price target (up previously from $92.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday, June 18th. Piper Sandler raised their price objective on Verona Pharma PLC American Depositary Share from $76.00 to $160.00 and gave the company an "overweight" rating in a research report on Monday. Jefferies Financial Group lifted their price objective on Verona Pharma PLC American Depositary Share from $95.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Finally, Wells Fargo & Company boosted their target price on Verona Pharma PLC American Depositary Share from $107.00 to $138.00 and gave the stock an "overweight" rating in a report on Friday, June 20th. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $101.10.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.